Stock Research: Pfizer Limited

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Pfizer Limited

BSE:500680 INE182A01018
85
  • Value
    94
  • Growth
    45
  • Safety
    Safety
    33
  • Combined
    66
  • Sentiment
    82
  • 360° View
    360° View
    85
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pfizer Limited is an India-based multinational pharmaceutical company. It focuses on Vaccines (Prevenar 13), Hospitals (advanced anti-infectives), Internal Medicine (respiratory, gastrointestinal, pain, cardiovascular), and Inflammation and Immunology (chronic autoimmune diseases, with brands like Enbrel). In the last fiscal year, the company had a market cap of $2848 million, profits of $166 million, and revenue of $267 million, with 1598 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 85 (better than 85% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Pfizer Limited are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Pfizer Limited. The consolidated Sentiment Rank has a good rank of 82, which means that professional investors are more optimistic about the stock than for 82% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 94 or better than 94% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 33, meaning that the share price of Pfizer Limited is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 45. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 55 39 33
Growth
45 15 37 25
Safety
Safety
94 76 72 65
Sentiment
82 43 57 14
360° View
360° View
85 44 59 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 87 95 87
Opinions Change
50 23 50 50
Pro Holdings
n/a 51 58 6
Market Pulse
45 12 3 11
Sentiment
82 43 57 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 55 39 33
Growth
45 15 37 25
Safety Safety
94 76 72 65
Combined
66 48 47 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
41 53 39 37
Price vs. Earnings (P/E)
15 19 14 16
Price vs. Book (P/B)
38 55 45 31
Dividend Yield
54 60 63 60
Value
33 55 39 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
37 39 42 16
Profit Growth
70 39 27 65
Capital Growth
8 7 96 42
Stock Returns
71 35 29 31
Growth
45 15 37 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
73 74 66 78
Refinancing
72 64 66 46
Liquidity
78 61 63 61
Safety Safety
94 76 72 65

Similar Stocks

Discover high‑ranked alternatives to Pfizer Limited and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Rede D'Or São Luiz

BOVESPA:RDOR3
Country: Brazil
Industry: Health Care Facilities
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.